Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11680353 | 0.77 | TSHR (0.46) | ESR1ESR2KCNN4RAB9ALMNA | |
| SCHEMBL21164691 | 0.77 | ESR1 (0.46) | ESR1ESR2ARKCNN4HTR7 | |
| SCHEMBL25101398 | 0.76 | ESR1 (0.48) | ESR1ESR2ARKCNN4HTR7 | |
| SCHEMBL19232109 | 0.76 | CNR2 (0.42) | ESR1ESR2ARKCNN4ACHE | |
| SCHEMBL19226355 | 0.74 | ALDH1A1 (0.49) | ESR1ESR2ARKCNN4HTR7 | |
| SCHEMBL6700733 | 0.74 | ESR1 (0.38) | ESR1ESR2ARKCNN4HTR7 | |
| SCHEMBL10946254 | 0.72 | KCNN4 (0.32) | KCNN4ACHERAB9AUSP2LMNA | |
| SCHEMBL12902478 | 0.72 | ESR1 (0.36) | ESR1ESR2ARKCNN4HTR7 | |
| SCHEMBL19982129 | 0.72 | ESR1 (0.36) | ESR1ESR2ARKCNN4HTR7 | |
| SCHEMBL27488131 | 0.71 | KCNN4 (0.40) | CACNA1GKCNN4HTR7HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1814851-B1 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2013-06-05 | — | — | EP | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
| EP-1814851-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040181-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2006-04-20 | — | — | WO | disclosed |
| EP-1289957-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001087839-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
| EP-1059922-A2 | GLYCINE TRANSPORT INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999044596-A2 | GLYCINE TRANSPORT INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-10 | — | — | WO | disclosed |
| US-4810792-A | HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1989-03-07 | — | — | US | disclosed |
| US-4788201-A | HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0275962-A2 | 3-Methylenespiro [benzofuran-piperidines], intermediates and a process for the preparation thereof, and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-07-27 | — | — | EP | disclosed |
| US-4134982-A | Antipsychotic 1-[4,4-Bis(4-fluorophenyl) butyl]-4-phenoxy-1,2,3,6-tetrahydropyridines | WARNER-LAMBERT COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4128552-A | ANTIPSYCHOTIC | WARNER-LAMBERT COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | ESR1 3371/4885ESR2 3968/4885CACNA1G 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.